ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Malathion-induced neurological alterations associated with dysregulation of RORγt/STAT3/IL-17 and FOXP3/STAT5/IL-10 pathways: potential neuroprotective effects of BCG.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite their effectiveness in agriculture to control a variety of pests, organophosphorus compounds (OPC) such as malathion were linked with neurological dysfunctions and possibly death. The present study aimed to investigate the impact of OPC exposure on neuroinflammation via disrupting the equilibrium between pro-inflammatory (RORγt/STAT3/IL-17/IL-22) and anti-inflammatory (FOXP3/STAT5/IL-10) pathways. The study extended to evaluate the potential of BCG vaccination in alleviating neuroinflammation. Rats were distributed into four groups: control, malathion-intoxicated group, BCG-treated group, and scopolamine-treated group. Behavioral tests and histopathological investigations of the cerebral cortex were done. FOXP3, RORγt, STAT3, and STAT5 were estimated using qRT-PCR. Acetylcholine (Ach), BDNF, IL-10, IL-17, IL-22, BCL2, and BAX were estimated using ELISA, whereas GFAP and IL-1β were estimated via immunohistochemical analysis. The malathion-intoxicated group revealed higher gene expression of RORγt and STAT3, along with lower gene expression of FOXP3 and STAT5, compared with the control group. Moreover, the concentrations of IL-17, IL-22, and BAX were higher, along with lower concentrations of BDNF, IL-10, and BCL2, compared with the control group. Furthermore, GFAP and IL-1β showed marked positive cytoplasmic expression. However, the BCG-treated group reversed all the abovementioned findings. Collectively, the study highlights that malathion induces neuroinflammation via skewing the balance between the proinflammatory (RORγt/STAT3/IL-17/IL-22) and the antiinflammatory (FOXP3/STAT5/IL-10), leading to behavioral fluctations and brain's histological disruption. This imbalance resulted in cytokine production, neuronal apoptosis, and neurodegeneration. BCG administration alleviates these effects owing to its anti-inflammatory and neuroprotective effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.